Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?

Renal cell carcinoma (RCC) is the third most common genitourinary cancer accounting for approximately 180,000 deaths worldwide in 2020. Although over two-thirds of patients initially present localized disease, up to 50% of them may progress to metastatic disease. Adjuvant therapy aims to reduce the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosso, Federica, Roviello, Giandomenico, Nesi, Gabriella, Shabani, Sonia, Spatafora, Pietro, Villari, Donata, Catalano, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959913/
https://www.ncbi.nlm.nih.gov/pubmed/36835654
http://dx.doi.org/10.3390/ijms24044243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959913/
https://www.ncbi.nlm.nih.gov/pubmed/36835654
http://dx.doi.org/10.3390/ijms24044243

Ejemplares similares